Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twelve analysts that are presently covering the stock, Marketbeat.com reports. One ...

REGENXBIO is a longtime player in the gene therapy space, but one that’s yet to bring its own therapy to market (in the early ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will ...

Read Our Latest Report on REGENXBIO REGENXBIO Stock Performance Shares of NASDAQ:RGNX opened at $7.88 on Friday. The company has a market capitalization of $390.38 million, a P/E ratio of -1.57 ...

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

Regenxbio (RGNX) closed the last trading session at $7.95, gaining 1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...

In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a ...

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...

Japan’s Nippon Shinyaku is continuing to scoop up the international rights to some intriguing drugs, this time penning a $686 ...

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...

Regenxbio (RGNX) closed the last trading session at $7.95, gaining 1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...